News

NeurologyLive Editor in Chief Stephen D. Silberstein, MD discusses the importance of reaching a treatment effect that makes a significant difference in patients' lives.

Data from the phase 3b FOCUS trial demonstrates fremanezumab’s superior efficacy and tolerability in the prevention of migraine.

The child neurology resident at NYU Langone spoke about ways for residents to identify and address impaired colleagues that suffer from depression and burnout.

The professor of neurology at the Icahn School of Medicine at Mount Sinai discussed what still needs to be done to clarify medical marijuana’s position in medicine.

A 23-year-old male college student presents with first generalized tonic-clonic seizure followed by episodes of violent psychosis.

New findings have suggested dementia is a result of worsened white matter rarefaction, phosphorylated tau, and arteriolosclerosis due to repeated head trauma in former football players with CTE.

Boston Scientific’s Vercise Gevia deep brain stimulation system labels will allow for clinical use of stimulation during full-body MRI in patients with Parkinson disease, with an improved battery.

The regulatory agency cited 2 concerns in the complete response letter: the risk of infections related to intravenous infusion ports and renal toxicity.

The director of the Sleep-Wake Disorders Center at Montefiore Medical Center will offer further insights on narcolepsy at the upcoming International Congress on the Future of Neurology, September 27-28, 2019 in New York City.

Those with an existing inventory of eletriptan hydrobromide 40 mg tablets, lots AR5407 and CD4565, should stop use and distribution, and quarantine immediately.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Reisa Sperling, MD.

The investigational candidate is the subject of a phase 3 study assessing efficacy and safety in adults with hATTR amyloidosis with transthyretin mutation.

The director of the MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the ongoing efforts in drug development and what the ideal future may hold for migraine medicine.